Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A life-threatening, rapidly progressive thrombotic disorder affecting mainly neonates and children that is characterized by purpuric skin lesions and disseminated intravascular coagulation. PF may progress rapidly to multi-organ failure caused by thrombotic occlusion of small and medium-sized blood vessels. There are two forms of PF that are classified according to triggering mechanisms: acute infectious (the most common form), and idiopathic PF.
Features include common findings: Skin rash, Acrocyanosis, Low platelet count (thrombocytopenia), and Abnormal thrombosis and others; and sometimes findings: Hepatic failure, Intracranial hemorrhage, Neoplasm, and Internal hemorrhage and others. 25 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 3 | Skin rash, Abnormal blistering of the skin, Erythematous macule |
Phenotype severity distribution: 19 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for acquired purpura fulminans.
4 publications have been identified in PubMed for acquired purpura fulminans. Research spans Review / Meta-Analysis (50%), Other (25%), and Case Report / Case Series (25%).
Ramos Huamancondor C (2026). [PMID: 41755934](https://pubmed.ncbi.nlm.nih.gov/41755934/). *Cureus*. [Case Report / Case Series]
Theron A (2025). [PMID: 40548846](https://pubmed.ncbi.nlm.nih.gov/40548846/). *Acta Paediatr*. [Review / Meta-Analysis]
Garaz R (2024). [PMID: 38937414](https://pubmed.ncbi.nlm.nih.gov/38937414/). *Int Urol Nephrol*. [Other]
Gouia HF (2024). [PMID: 39031343](https://pubmed.ncbi.nlm.nih.gov/39031343/). *Clin Hemorheol Microcirc*. [Review / Meta-Analysis]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired purpura fulminans
Blood and immune system |
2 |
Low platelet count (thrombocytopenia), Disseminated intravascular coagulation |
Lab test results | 1 | Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration) |
Eyes | 1 | Macular purpura |
Digestive system | 1 | Hepatic failure |
Heart and blood vessels | 1 | Intracranial hemorrhage |
Neoplasm | 1 | Neoplasm |
AI-curated news mentioning acquired purpura fulminans
Updated Sep 15, 2026
A recent study highlights a case of acquired immune thrombotic thrombocytopenic purpura (aTTP) following transaxillary transcatheter aortic valve replacement, emphasizing its potential as a rare and life-threatening hematologic emergency. This discovery may inform clinical practices and patient management strategies.